Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits

详细信息    查看全文

• 作者：Bj?rn H Ebdrup (1)
  Filip K Knop (2)
  Pelle L Ish?y (1)
  Egill Rostrup (3)
  Birgitte Fagerlund (1)
  Henrik Lublin (1)
  Birte Glenth?j (1)
  
• 关键词：Schizophrenia ; antipsychotic medication ; overweight ; diabetes ; GLP ; 1 ; exenatide ; liraglutide ; neuroprotection ; cognition
• 刊名：BMC Medicine
• 出版年：2012
• 出版时间：December 2012
• 年：2012
• 卷：10
• 期：1
• 全文大小：179KB
• 参考文献：1. McGrath J, Saha S, Chant D, Welham J: Schizophrenia: a concise overview of incidence, prevalence, and mortality. / Epidemiol Rev 2008, 30:67-6. CrossRef
  2. Newcomer JW, Hennekens CH: Severe mental illness and risk of cardiovascular disease. / JAMA 2007, 298:1794-796. CrossRef
  3. Kolotkin RL, Corey-Lisle PK, Crosby RD, Swanson JM, Tuomari AV, L'italien GJ, Mitchell JE: Impact of obesity on health-related quality of life in schizophrenia and bipolar disorder. / Obesity (Silver Spring) 2008, 16:749-54. CrossRef
  4. Due P, Heitmann BL, Sorensen TI: Prevalence of obesity in Denmark. / Obes Rev 2007, 8:187-89. CrossRef
  5. Neovius M, Janson A, Rossner S: Prevalence of obesity in Sweden. / Obes Rev 2006, 7:1-. CrossRef
  6. Belanger-Ducharme F, Tremblay A: Prevalence of obesity in Canada. / Obes Rev 2005, 6:183-86. CrossRef
  7. Baskin ML, Ard J, Franklin F, Allison DB: Prevalence of obesity in the United States. / Obes Rev 2005, 6:5-. CrossRef
  8. Hoang U, Stewart R, Goldacre MJ: Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999-006. / BMJ 2011, 343:d5422. CrossRef
  9. Herrera BM, Lindgren CM: The genetics of obesity. / Curr Diab Rep 2010, 10:498-05. CrossRef
  10. Hansen T, Ingason A, Djurovic S, Melle I, Fenger M, Gustafsson O, Jakobsen KD, Rasmussen HB, Tosato S, Rietschel M, Frank J, Owen M, Bonetto C, Suvisaari J, Thygesen JH, Pétursson H, L?nnqvist J, Sigurdsson E, Giegling I, Craddock N, O'Donovan MC, Ruggeri M, Cichon S, Ophoff RA, Pietil?inen O, Peltonen L, N?then MM, Rujescu D, St Clair D, Collier DA Andreassen OA, Werge T: At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia. / Biol Psychiatry 2011, 70:59-3. CrossRef
  11. Mukundan A, Faulkner G, Cohn T, Remington G: Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. / Cochrane Database Syst Rev 2010, CD006629.
  12. Tandon R, Nasrallah HA, Keshavan M: Antipsychotics, mortality and schizophrenia: What are the facts? / Schizophr Res 2011, 133:262-63. CrossRef
  13. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S: Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. / Schizophr Res 2010, 123:225-33. CrossRef
  14. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: a comprehensive research synthesis. / Am J Psychiatry 1999, 156:1686-696.
  15. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA: Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. / Am J Psychiatry 2003, 160:290-96. CrossRef
  16. Fuller BE, Rodriguez VL, Linke A, Sikirica M, Dirani R, Hauser P: Prevalence of liver disease in veterans with bipolar disorder or schizophrenia. / Gen Hosp Psychiatry 2011, 33:232-37. CrossRef
  17. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr, International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. / Circulation 2009, 120:1640-645. CrossRef
  18. Sikorski C, Luppa M, Kaiser M, Glaesmer H, Schomerus G, K?nig HH, Riedel-Heller SG: The stigma of obesity in the general public and its implications for public health - a systematic review. / BMC Public Health 2011, 11:661. CrossRef
  19. Dixon JB: The effect of obesity on health outcomes. / Mol Cell Endocrinol 2010, 316:104-08. CrossRef
  20. / WHO: The World Health Report : 2001 : Mental health : new understanding, new hope. 2001.
  21. Withrow D, Alter DA: The economic burden of obesity worldwide: a systematic review of the direct costs of obesity. / Obes Rev 2011, 12:131-41. CrossRef
  22. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M: Health and economic burden of the projected obesity trends in the USA and the UK. / Lancet 2011, 378:815-25. CrossRef
  23. Hulshoff Pol HE, Kahn RS: What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. / Schizophr Bull 2008, 34:354-66. CrossRef
  24. Jagust W: What can imaging reveal about obesity and the brain? / Curr Alzheimer Res 2007, 4:135-39. CrossRef
  25. Gabriele JM, Dubbert PM, Reeves RR: Efficacy of behavioural interventions in managing atypical antipsychotic weight gain. / Obes Rev 2009, 10:442-55. CrossRef
  26. Maayan L, Vakhrusheva J, Correll CU: Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. / Neuropsychopharmacology 2010, 35:1520-530. CrossRef
  27. Mitri J, Hamdy O: Diabetes medications and body weight. / Expert Opin Drug Saf 2009, 8:573-84. CrossRef
  28. Evans S, Newton R, Higgins S: Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. / Aust N Z J Psychiatry 2005, 39:479-86.
  29. Centorrino F, Wurtman JJ, Duca KA, Fellman VH, Fogarty KV, Berry JM, Guay DM, Romeling M, Kidwell J, Cincotta SL, Baldessarini RJ: Weight loss in overweight patients maintained on atypical antipsychotic agents. / Int J Obes (Lond) 2006, 30:1011-016. CrossRef
  30. Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, He YQ, Liu YJ, Chen JD, Li LH: Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. / JAMA 2008, 299:185-93. CrossRef
  31. Ben-David K, Rossidis G: Bariatric surgery: indications, safety and efficacy. / Curr Pharm Des 2011, 17:1209-217. CrossRef
  32. Gibson CD, Carnell S, Ochner CN, Geliebter A: Neuroimaging, gut peptides and obesity: novel studies of the neurobiology of appetite. / J Neuroendocrinol 2010, 22:833-45.
  33. Neary MT, Batterham RL: Gut hormones: implications for the treatment of obesity. / Pharmacol Ther 2009, 124:44-6. CrossRef
  34. Holst JJ: The physiology of glucagon-like peptide 1. / Physiol Rev 2007, 87:1409-439. CrossRef
  35. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL: Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. / BMJ 2012, 344:d7771. CrossRef
  36. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L, Rasmussen MF, Rissanen A, R?ssner S, Savolainen MJ, Van Gaal L: Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. / Int J Obes (Lond) 2012, 36:890. CrossRef
  37. Sharma S, Mells JE, Fu PP, Saxena NK, Anania FA: GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. / PLoS One 2011, 6:e25269. CrossRef
  38. Mells JE, Fu PP, Sharma S, Olson DE, Cheng L, Handy JA, Saxena NK, Sorescu D, Anania FA: GLP-1 analog, liraglutide ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. / Am J Physiol Gastrointest Liver Physiol 2012, 302:G225-35. CrossRef
  39. Lykkegaard K, Larsen PJ, Vrang N, Bock C, Bock T, Knudsen LB: The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance. / Schizophr Res 2008, 103:94-03. CrossRef
  40. Amori RE, Lau J, Pittas AG: Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. / JAMA 2007, 298:194-06. CrossRef
  41. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ, Haile CN: Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. / Nat Med 2003, 9:1173-179. CrossRef
  42. Holst JJ, Burcelin R, Nathanson E: Neuroprotective properties of GLP-1: theoretical and practical applications. / Curr Med Res Opin 2011, 27:547-58. CrossRef
  43. McClean PL, Parthsarathy V, Faivre E, Holscher C: The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. / J Neurosci 2011, 31:6587-594. CrossRef
  44. McClean PL, Gault VA, Harriott P, Holscher C: Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. / Eur J Pharmacol 2010, 630:158-62. CrossRef
  45. Bertilsson G, Patrone C, Zachrisson O, Andersson A, Dannaeus K, Heidrich J, Kortesmaa J, Mercer A, Nielsen E, R?nnholm H, Wikstr?m L: Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. / J Neurosci Res 2008, 86:326-38. CrossRef
  46. Martin B, Golden E, Carlson OD, Pistell P, Zhou J, Kim W, Frank BP, Thomas S, Chadwick WA, Greig NH, Bates GP, Sathasivam K, Bernier M, Maudsley S, Mattson MP, Egan JM: Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. / Diabetes 2009, 58:318-28. CrossRef
  47. Shenton ME, Kikinis R, Jolesz FA, Pollak SD, LeMay M, Wible CG, Hokama H, Martin J, Metcalf D, Coleman M: Abnormalities of the left temporal lobe and thought disorder in schizophrenia. A quantitative magnetic resonance imaging study. / N Engl J Med 1992, 327:604-12. CrossRef
  48. Vita A, De Peri L, Silenzi C, Dieci M: Brain morphology in first-episode schizophrenia: a meta-analysis of quantitative magnetic resonance imaging studies. / Schizophr Res 2006, 82:75-8. CrossRef
  49. Steen RG, Mull C, McClure R, Hamer RM, Lieberman JA: Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. / Br J Psychiatry 2006, 188:510-18. CrossRef
  50. Ebdrup BH, Glenthoj B, Rasmussen H, Aggernaes B, Langkilde AR, Paulson OB, Lublin H, Skimminge A, Baaré W: Hippocampal and caudate volume reductions in antipsychotic-naive first-episode schizophrenia. / J Psychiatry Neurosci 2010, 35:95-04. CrossRef
  51. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W, Schizophrenia Patient Outcomes Research Team (PORT): The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. / Schizophr Bull 2010, 36:71-3. CrossRef
  52. Gunstad J, Paul RH, Cohen RA, Tate DF, Spitznagel MB, Grieve S, Gordon E: Relationship between body mass index and brain volume in healthy adults. / Int J Neurosci 2008, 118:1582-593. CrossRef
  53. Taki Y, Kinomura S, Sato K, Inoue K, Goto R, Okada K, Uchida S, Kawashima R, Fukuda H: Relationship between body mass index and gray matter volume in 1,428 healthy individuals. / Obesity (Silver Spring) 2008, 16:119-24. CrossRef
  54. Pannacciulli N, Del Parigi A, Chen K, Le DS, Reiman EM, Tataranni PA: Brain abnormalities in human obesity: a voxel-based morphometric study. / Neuroimage 2006, 31:1419-425. CrossRef
  55. Gazdzinski S, Kornak J, Weiner MW, Meyerhoff DJ: Body mass index and magnetic resonance markers of brain integrity in adults. / Ann Neurol 2008, 63:652-57. CrossRef
  56. Gazdzinski S, Millin R, Kaiser LG, Durazzo TC, Mueller SG, Weiner MW, Meyerhoff DJ: BMI and neuronal integrity in healthy, cognitively normal elderly: a proton magnetic resonance spectroscopy study. / Obesity (Silver Spring) 2010, 18:743-48. CrossRef
  57. Willeumier KC, Taylor DV, Amen DG: Elevated BMI is associated with decreased blood flow in the prefrontal cortex using SPECT imaging in healthy adults. / Obesity (Silver Spring) 2011, 19:1095-097. CrossRef
  58. Pinkham A, Loughead J, Ruparel K, Wu WC, Overton E, Gur R, Gur R: Resting quantitative cerebral blood flow in schizophrenia measured by pulsed arterial spin labeling perfusion MRI. / Psychiatry Res 2011, (194):64-2.
  59. Stanek KM, Grieve SM, Brickman AM, Korgaonkar MS, Paul RH, Cohen RA, Gunstad JJ: Obesity is associated with reduced white matter integrity in otherwise healthy adults. / Obesity (Silver Spring) 2011, 19:500-04. CrossRef
  60. Kyriakopoulos M, Bargiotas T, Barker GJ, Frangou S: Diffusion tensor imaging in schizophrenia. / Eur Psychiatry 2008, 23:255-73. CrossRef
  61. Maayan L, Hoogendoorn C, Sweat V, Convit A: Disinhibited eating in obese adolescents is associated with orbitofrontal volume reductions and executive dysfunction. / Obesity (Silver Spring) 2011, 19:1382-387. CrossRef
  62. Dazzan P, Soulsby B, Mechelli A, Wood SJ, Velakoulis D, Phillips LJ, Yung AR, Chitnis X, Lin A, Murray RM, McGorry PD, McGuire PK, Pantelis C: Volumetric abnormalities predating the onset of schizophrenia and affective psychoses: an MRI study in subjects at ultrahigh risk of psychosis. / Schizophr Bull 2011, in press.
  63. Peters A, Bosy-Westphal A, Kubera B, Langemann D, Goele K, Later W, Heller M, Hubold C, Müller MJ: Why doesn't the brain lose weight, when obese people diet? / Obes Facts 2011, 4:151-57. CrossRef
  64. Siervo M, Arnold R, Wells JC, Tagliabue A, Colantuoni A, Albanese E, Brayne C, Stephan BC: Intentional weight loss in overweight and obese individuals and cognitive function: a systematic review and meta-analysis. / Obes Rev 2011, 12:968-83. CrossRef
  65. DelParigi A, Pannacciulli N, Le DN, Tataranni PA: In pursuit of neural risk factors for weight gain in humans. / Neurobiol Aging 2005,26(Suppl 1):50-5. CrossRef
  66. Benetti S, Mechelli A, Picchioni M, Broome M, Williams S, McGuire P: Functional integration between the posterior hippocampus and prefrontal cortex is impaired in both first episode schizophrenia and the at risk mental state. / Brain 2009, 132:2426-436. CrossRef
  67. Burger KS, Stice E: Variability in reward responsivity and obesity: evidence from brain imaging studies. / Curr Drug Abuse Rev 2011, 4:182-89. CrossRef
  68. Nielsen MO, Rostrup E, Wulff S, Bak N, Lublin H, Kapur S, Glenth?j B: Alterations of the brain reward system in antipsychotic naive schizophrenia patients. / Biol Psychiatry 2012, 71:898-05. CrossRef
  69. Brinkworth GD, Buckley JD, Noakes M, Clifton PM, Wilson CJ: Long-term effects of a very low-carbohydrate diet and a low-fat diet on mood and cognitive function. / Arch Intern Med 2009, 169:1873-880. CrossRef
  70. Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults ClinicalTrials.gov http://clinicaltrials.gov/ct2/show/NCT00845507
  71. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU: Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. / Nat Rev Endocrinol 2011, 18:114-26. CrossRef
  72. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A: Glucagon-like peptide analogues for type 2 diabetes mellitus. / Cochrane Database Syst Rev 2011, CD006423.
  73. Grant P, Lipscomb D, Quin J: Psychological and quality of life changes in patients using GLP-1 analogues. / J Diabetes Complications 2011, 25:244-46. CrossRef
  74. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1741-7015/10/92/prepub
  
• 作者单位：Bj?rn H Ebdrup (1)
  Filip K Knop (2)
  Pelle L Ish?y (1)
  Egill Rostrup (3)
  Birgitte Fagerlund (1)
  Henrik Lublin (1)
  Birte Glenth?j (1)
  
  1. Center for Neuropsychiatric Schizophrenia Research, CNSR and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, Psychiatric Center Glostrup, University of Copenhagen, DK-2600, Glostrup, Denmark
  2. Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, DK-2900, Hellerup, Denmark
  3. Functional Imaging Unit, FIUnit, Glostrup Hospital, University of Copenhagen, DK-2600, Glostrup, Denmark
  

文摘

Background Antipsychotic-induced weight gain constitutes a major unresolved clinical problem which may ultimately be associated with reducing life expectancy by 25 years. Overweight is associated with brain deterioration, cognitive decline and poor quality of life, factors which are already compromised in normal weight patients with schizophrenia. Here we outline the current strategies against antipsychotic-induced weight gain, and we describe peripheral and cerebral effects of the gut hormone glucagon-like peptide-1 (GLP-1). Moreover, we account for similarities in brain changes between schizophrenia and overweight patients. Discussion Current interventions against antipsychotic-induced weight gain do not facilitate a substantial and lasting weight loss. GLP-1 analogs used in the treatment of type 2 diabetes are associated with significant and sustained weight loss in overweight patients. Potential effects of treating schizophrenia patients with antipsychotic-induced weight gain with GLP-1 analogs are discussed. Conclusions We propose that adjunctive treatment with GLP-1 analogs may constitute a new avenue to treat and prevent metabolic and cerebral deficiencies in schizophrenia patients with antipsychotic-induced weight gain. Clinical research to support this idea is highly warranted.